Vertex Pharmaceuticals Incorporated (VRTX): BMO Sees 3% Upside Today, Lifts PT to $132

Vertex Pharmaceuticals Incorporated (VRTX): BMO Sees 3% Upside Today, Lifts PT to $132

Solid Orkambi quarter for Vertex is expected to sustain future positive momentum, according to BMO Capital analyst


Vertex Pharmaceuticals Incorporated (VRTX): Credit Suisse Raised Its Probability Of Success To 75% To The Triplet In HetMin Population

Vertex beat on the top and bottom line with $481M vs. $459M consensus and $0.41 vs. $0.35 non-GAAP EPS consensus

Sarepta Therapeutics Inc (NASDAQ:SRPT) Raised Guidance To $95M As The Launch Continues To Look Highly Encouraging

Credit Suisse’s new 2017 estimate is $103M which is higher than its previous estimate of $89M

Q1'17 Will Likely Be an Uninspiring Quarter for Pfizer Inc (PFE)

BMO forecasts flat revenue, flat opex, ~3% lower net income, offset by share buybacks to deliver flat y/y EPS

Freeport-McMoRan Inc's (FCX) Positive Operational Outlook

The firm has updated its model to reflect operational guidance provided by Freeport following its receipt of a temporary copper concentrate export permit from the gov't of Indonesia

BMO Thinks Halliburton Company (HAL) is the Best-Positioned Large Cap in the Only Market that is Growing

Halliburton's call offered little new information but confirmed BMO's positive view of Halliburton's leading position in U.S. land, the lone bright spot in the world

BioMarin Pharmaceutical Inc. (BMRN) Brineura Wins CHMP Recommendation

BMO Capital Markets continues to believe the data supports approval of Brineura for Battens disease and are encouraged by CHMP allowing use in younger patients (0-2 year olds) and the company reaching labeling discussion stage with the FDA